Emerald Member: Sunovion

Over the course of five years, Sunovion has contributed clinical advances and new treatment options, and has led advocacy and educational initiatives with cross-sector coalitions focused on the advancement of research, innovation and improvements in healthcare.

Our track record of discovery, development and commercialization of important therapies includes Brovana® (arformoterol tartrate), Latuda® (lurasidone HCl), and Aptiom® (eslicarbazepine acetate). Our approved therapies also include Utibron™ Neohaler® (indacaterol and glycopyrrolate) Inhalation Powder, Seebri™ Neohaler® (glycopyrrolate) Inhalation Powder, Arcapta® Neohaler® (indacaterol) Inhalation Powder.

Sunovion has a robust portfolio and is expanding leadership in treatments for psychiatric, neurologic and respiratory conditions.

Company Details

Expertise:

Categories:

Website:

Sunovion